◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › X › XNCR

Xencor Inc (XNCR) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-06

Xencor Inc (XNCR) operates in the BIOTECHNOLOGY industry and is headquartered in Pasadena, United States with about 260 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, XNCR reported $126M in revenue and ($92M) in net income.

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases.

Interactive charts & full statements → Open the XNCR valuation workbench →

XNCR Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Total Revenue	$105M	$126M	$110M	$168M	$165M	$275M	$123M	$157M	$41M	$36M	$88M	$28M	$10M	$10M	$10M	$7M
Gross Profit	$45M	$115M	($117M)	($85M)	$165M	$275M	$123M	$38M	$41M	$36M	$88M	$28M	($9M)	($7M)	($3M)	$7M
Gross Margin %	43.3%	91.6%	-106.1%	-50.6%	100.0%	100.0%	100.0%	24.3%	100.0%	100.0%	100.0%	100.0%	-94.5%	-67.1%	-33.0%	100.0%
Operating Income (EBIT)	($216M)	($178M)	($178M)	($139M)	($82M)	$44M	($77M)	$14M	($79M)	($54M)	$23M	($18M)	($16M)	($11M)	($6M)	($9M)
Operating Margin %	-205.8%	-141.3%	-161.5%	-82.4%	-50.1%	15.9%	-62.6%	8.8%	-195.5%	-150.0%	25.8%	-66.0%	-172.9%	-103.4%	-65.4%	-138.0%
Net Income	($163M)	($92M)	($233M)	($126M)	($55M)	$83M	($64M)	$27M	($70M)	($49M)	$24M	($18M)	($16M)	($60M)	($9M)	($11M)
Net Margin %	-155.6%	-73.2%	-210.5%	-74.9%	-33.5%	30.0%	-51.8%	17.2%	-173.4%	-137.0%	27.0%	-63.4%	-172.5%	-592.4%	-90.2%	-163.6%
EBITDA	($124M)	($47M)	($186M)	($126M)	($74M)	$51M	($71M)	$18M	($76M)	($52M)	$24M	($17M)	($16M)	($58M)	($6M)	($9M)
Earnings Per Share (EPS)	$-2.17	$-1.24	$-3.58	$-2.08	$-0.93	$1.37	$-1.11	$0.46	$-1.31	$-1.05	$0.56	$-0.45	$-0.52	$-1.92	$-0.51	$-0.67
Shares Outstanding (M)	76M	74M	65M	61M	60M	60M	57M	58M	54M	47M	42M	39M	31M	31M	17M	17M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

XNCR Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$51M	$5M	$28M	$21M	$44M	$33M	$70M	$18M
Gross Profit	$51M	$2M	$26M	($33M)	$41M	$30M	$70M	($40M)
Gross Margin %	100.0%	43.2%	90.9%	-158.9%	93.9%	91.8%	100.0%	-227.2%
Operating Income (EBIT)	($37M)	($78M)	($54M)	($48M)	($33M)	($43M)	$4M	($55M)
Operating Margin %	-72.4%	-1724.1%	-189.9%	-226.3%	-76.1%	-131.9%	5.8%	-310.2%
Net Income	($22M)	($129M)	($7M)	($6M)	($31M)	($48M)	($53M)	($46M)
Net Margin %	-42.4%	-2854.7%	-23.6%	-28.7%	-70.7%	-147.9%	-76.4%	-260.1%
EBITDA	($12M)	($121M)	$6M	$4M	($20M)	($37M)	($16M)	($35M)
Earnings Per Share (EPS)	$-0.29	$-1.71	$-0.09	$-0.08	$-0.41	$-0.66	$-0.73	$-0.72
Shares Outstanding (M)	76M	75M	74M	74M	74M	74M	73M	64M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

XNCR Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Cash from Operations (CFO)	($206M)	($135M)	($202M)	$85M	$24M	($17M)	($5M)	$64M	($80M)	($34M)	$95M	$27M	($21M)	($5M)	($11M)	($1M)
Capital Expenditures (CapEx)	$2M	$3M	$6M	$21M	$43M	$16M	$14M	$11M	$9M	$7M	$3M	$4M	$2M	$1M	$1M	$1M
Free Cash Flow (FCF)	($208M)	($138M)	($208M)	$64M	($19M)	($33M)	($19M)	$53M	($89M)	($41M)	$92M	$23M	($24M)	($7M)	($12M)	($3M)
FCF Margin %	-198.4%	-110.1%	-188.5%	37.9%	-11.5%	-11.9%	-15.3%	34.0%	-219.0%	-114.7%	104.7%	82.8%	-248.3%	-66.3%	-129.2%	-36.6%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

XNCR Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($56M)	($68M)	($52M)	($31M)	($36M)	($16M)	($56M)	($26M)
Capital Expenditures (CapEx)	$1M	$1M	$1M	$0M	$0M	$1M	$3M	$2M
Free Cash Flow (FCF)	($56M)	($68M)	($53M)	($31M)	($37M)	($18M)	($58M)	($28M)
FCF Margin %	-109.7%	-1511.0%	-187.2%	-147.6%	-84.3%	-54.0%	-83.2%	-158.1%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

XNCR Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Total Assets	$725M	$875M	$952M	$953M	$846M	$838M	$703M	$670M	$577M	$390M	$429M	$207M	$68M	$87M	$12M	$22M
Cash & Cash Equivalents	$45M	$54M	$41M	$54M	$54M	$143M	$164M	$50M	$26M	$17M	$15M	$13M	$55M	$78M	$2M	$15M
Total Liabilities	$222M	$240M	$278M	$284M	$119M	$105M	$131M	$77M	$55M	$108M	$115M	$44M	$9M	$14M	$31M	$33M
Total Debt (Short + Long-Term)	$81M	$123M	$167M	$24M	$5M	$34M	$2M	$2M	$10M	$5M	$7M	$0M	$0M	$0M	$21M	$18M
Total Shareholders' Equity	$503M	$636M	$678M	$669M	$727M	$734M	$572M	$593M	$522M	$282M	$314M	$162M	$59M	$74M	($20M)	($11M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive XNCR viewer.

Other Companies in BIOTECHNOLOGY

GHRS · GH Research PLC — $2 billion
COAG · Hemab Therapeutics Holdings, Inc. Common Stock — $2 billion
ZYME · Zymeworks Inc. Common Stock — $2 billion
FTRE · Fortrea Holdings Inc. — $2 billion
STOK · Stoke Therapeutics Inc — $2 billion
SEPN · Septerna, Inc. Common Stock — $2 billion
VIR · Vir Biotechnology Inc — $2 billion
TYRA · Tyra Biosciences Inc — $2 billion

← XNAV All “X” companies XNDD →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.